Cefepime hydrochloride

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。5月17日，据NMPA官网公示，悦康药业集团2款仿制药同日过评，分别为注射用头孢西丁钠和注射用头孢米诺钠。至此，悦康药业集团目前已有20款药物过评。截图来源：NMPA12亿+注射剂，悦康药业等16家药企过评注射用头孢西丁钠属于头孢类抗菌药物，它也是一种β-内酰胺类药物。适用于对本品敏感的细菌引起的感染，例如上下呼吸道感染、泌尿道感染包括无并发症的淋病、腹膜炎以及其它腹腔内、盆腔内感染、败血症(包括伤寒)、妇科感染、骨或关节软组织感染、心内膜炎。据药融云数据显示，注射用头孢西丁钠在2022年全国院内市场销售额超12亿元，同比增大达2.55%。截图来源：药融云全国医院销售数据库注射用头孢西丁钠在国内已有上海上药新亚药业、广州白云山医药集团、四川制药制剂等超60家药企拥有生产批文，其中过评的有山东鲁抗医药、四川制药制剂、扬子江药业、悦康药业等16家药企。截图来源：药融云过评药品汇总数据库 纳入第七批集采，10亿+品种悦康药业过评注射用头孢米诺钠为抗感染类药物，适用于治疗对头孢米诺敏感的链球菌属、肺炎链球菌、变形杆菌等引起的败血症、扁桃体炎、急性支气管炎、肺炎、慢性呼吸道病变继发感染等疾病。受疫情及带量采购等因素影响，近年来注射用头孢米诺钠市场持续萎缩。据药融云数据显示，注射用头孢米诺钠在2022全国院内销售超10亿元，同比下滑13.52%。截图来源：药融云全国医院销售数据库注射用头孢米诺钠已被纳入第七批集采,目前有80家药企拥有生产批文，其中有超20家企业过评，包括悦康药业集团、山东鲁抗医药、海南葫芦娃药业、苏州二叶制药、南昌立健药业、福安药业等。截图来源：药融云过评药品汇总数据库目前，悦康药业集团有注射用奥美拉唑钠、注射用头孢唑林钠、注射用盐酸头孢吡肟、奥美拉唑肠溶胶囊等20款品种过评，其中注射用头孢唑林钠、注射用头孢米诺钠、注射用头孢西丁钠、注射用艾司奥美拉唑钠4款是今年过评品种。END本文为原创文章，转载请留言获取授权 近期热门资源获取后台回复关键词“报告”，获取数十篇药融云出品独家报告后台回复关键词“CSCO”，获取2023CSCO指南后台回复关键词“ASCO”，获取2023ASCO分癌种摘要后台回复关键词“2023首仿”，获取2023年首仿药物获批名单后台回复关键词“医保”，获取2022年医保目录   联系我们，体验药融云更多专业服务会议合作园区服务数据库咨询定制服务媒体合作点击阅读原文，申请药融云企业版免费试用！

MALVERN, Pa.--(BUSINESS WIRE)-- Venatorx Pharmaceuticals, a private, pre-commercial pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections, announced today several changes to its executive leadership team. Manos Perros, PhD, has been appointed to the Board of Directors as Executive Chairman. Dr. Perros is a distinguished pharmaceutical and biotech executive with an impressive track record that includes more than 25 years in life sciences research and development. He was previously Chief Executive Officer and co-founder of Entasis Therapeutics, where he successfully positioned the company as a leader in the antimicrobial space, resulting in its acquisition by Innoviva in 2022. While at Entasis, Dr. Perros oversaw the development of Xacduro, which recently earned U.S. Food and Drug Administration approval as the first targeted treatment for Acinetobacter baumannii pneumonia. Prior to founding Entasis, Dr. Perros held the positions of Vice President and Head of AstraZeneca’s Infection Research and Early Development organization and Site Head for AstraZeneca’s Boston R&D research center. Dr. Perros also served as Director of the Novartis Institute for Tropical Diseases in Singapore, and Vice-President and Chief Scientific Officer, Antivirals, at Pfizer, where he led an R&D program that culminated in the approval of Selzentry, a first-in-class treatment for HIV. Dr. Perros’ appointment follows the resignation of Christopher J. Burns, Ph.D., who has stepped down as Chief Executive Officer and Director of Venatorx Pharmaceuticals. Additionally, Tomas J. Heyman has stepped down as Non-Executive Chairman of the Board. “On behalf of the entire Company, I would like to personally thank Chris for his dedication and tireless perseverance to lead Venatorx for over 14 years as an innovative pioneer in the fight against anti-microbial resistance. The Board of Directors sincerely appreciates his contributions along with the endless support and leadership that have guided the Company toward achieving its mission. I am delighted to join Venatorx Pharmaceuticals and to have an opportunity to help advance cefepime-taniborbactam through regulatory review and toward FDA approval to address the growing unmet need for novel treatments for patients suffering from multi-drug resistant gram-negative bacterial infections,” Dr. Perros said. “As recent Phase III data in The New England Journal of Medicine established, cefepime-taniborbactam met the primary noninferiority efficacy endpoint and demonstrated statistical superiority to meropenem for the treatment of complicated urinary tract infections (cUTIs), including acute pyelonephritis, while having a similar safety pro meropenem. This therapy has enormous potential and may represent a significant improvement over the standard of care that could support global health efforts to combat antibiotic-resistant infections for patients around the world.” About Venatorx Pharmaceuticals, Inc. Venatorx is a private, late-stage clinical pharmaceutical company focused on improving health outcomes for patients with multidrug-resistant bacterial infections and hard-to-treat viral infections. Venatorx’s lead program, cefepime-taniborbactam, is a clinical-stage antibiotic that successfully completed a Phase 3 study in adults with complicated urinary tract infections (cUTI), including pyelonephritis. In October 2022, BARDA awarded a contract of up to $318M for development and procurement of cefepime-taniborbactam for the treatment of melioidosis and multi-drug resistant infections. Venatorx is also developing an oral antibacterial, ceftibuten-ledaborbactam (formerly known as VNRX-7145), for the treatment of cUTI, including pyelonephritis, caused by certain bacteria in adult patients with limited treatment options; this product is completing Phase 1 and will advance directly to a global Phase 3 cUTI clinical trial. For more information about Venatorx and its anti-infectives portfolio, please visit . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding the potential, safety, efficacy, and regulatory and clinical development of Venatorx Pharmaceuticals’ product candidates.